Drugging the HDAC6-HSP90 interplay in malignant cells.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  TIPS - Trends in Pharmacological Sciences

• Publication date

  2014-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.tips.2014.08.001PMID 25234862
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exploiting epigenetic vulnerabilities for cancer therapeutics.

  2014cited by this paper
• 4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.

  2014cited by this paper
• Erasers of histone acetylation: the histone deacetylase enzymes.

  2014cited by this paper
• LC3B-II deacetylation by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation.

  2013cited by this paper
• Expression of CD133 in acute leukemia

  2013cited by this paper
• Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3.

  2013cited by this paper
• Development of a histone deacetylase 6 inhibitor and its biological effects

  2013cited by this paper
• tert‐Butylcarbamate‐Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells

  2013cited by this paper
• Inhibition of HDAC6 Deacetylase Activity Increases Its Binding with Microtubules and Suppresses Microtubule Dynamic Instability in MCF-7 Cells*

  2013cited by this paper
• STAT5 acetylation

  2013cited by this paper
• Tubulin Polymerization Promoting Protein 1 (Tppp1) Phosphorylation by Rho-associated Coiled-coil Kinase (Rock) and Cyclin-dependent Kinase 1 (Cdk1) Inhibits Microtubule Dynamics to Increase Cell Proliferation*

  2013cited by this paper
• The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation

  2013cited by this paper
• HSP90 Protects the Human T-Cell Leukemia Virus Type 1 (HTLV-1) Tax Oncoprotein from Proteasomal Degradation To Support NF-κB Activation and HTLV-1 Replication

  2013cited by this paper
• Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A.

  2013cited by this paper
• SIAH proteins: critical roles in leukemogenesis

  2013cited by this paper
• Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration*

  2013cited by this paper
• A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation

  2013cited by this paper
• Tubulin polymerization promoting protein 1 (TPPP1) increases β-catenin expression through inhibition of HDAC6 activity in U2OS osteosarcoma cells.

  2013cited by this paper
• A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth

  2013cited by this paper
• 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.

  2013cited by this paper
• C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances

  2013cited by this paper
• Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.

  2013cited by this paper
• Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

  2013cited by this paper
• Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.

  2012cited by this paper
• Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells.

  2012cited by this paper
• Modulation of Histone Deacetylase 6 (HDAC6) Nuclear Import and Tubulin Deacetylase Activity through Acetylation*

  2012cited by this paper
• Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

  2012cited by this paper
• A prescription for 'stress'--the role of Hsp90 in genome stability and cellular adaptation.

  2012cited by this paper
• HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.

  2012cited by this paper
• Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

  2012cited by this paper
• Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes

  2012cited by this paper
• A novel class of small molecule inhibitors of HDAC6.

  2012cited by this paper
• HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance

  2012cited by this paper
• Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation.

  2012cited by this paper
• Development and therapeutic impact of HDAC6-selective inhibitors.

  2012cited by this paper
• Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.

  2012cited by this paper
• Post-translational modifications of Hsp90 and their contributions to chaperone regulation.

  2012cited by this paper
• Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells

  2011cited by this paper
• The HTLV-1 Tax protein inhibits formation of stress granules by interacting with histone deacetylase 6

  2011cited by this paper
• A novel GRK2/HDAC6 interaction modulates cell spreading and motility

  2011cited by this paper
• PKC alpha regulates Sendai virus‐mediated interferon induction through HDAC6 and β‐catenin

  2011cited by this paper
• A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.

  2011cited by this paper
• Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress

  2011cited by this paper
• Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Inhibitors of HDACs--effective drugs against cancer?

  2010cited by this paper
• AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

  2010cited by this paper
• HDAC6 Regulates Mitochondrial Transport in Hippocampal Neurons

  2010cited by this paper
• The Role of HDAC6 in Cancer

  2010cited by this paper
• Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

  2010cited by this paper
• Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.

  2010cited by this paper
• Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.

  2010cited by this paper
• Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity.

  2009cited by this paper
• HDAC2: a critical factor in health and disease.

  2009cited by this paper
• Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.

  2009cited by this paper
• Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

  2009cited by this paper
• Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.

  2009cited by this paper
• Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

  2009cited by this paper
• Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.

  2008cited by this paper
• MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.

  2008cited by this paper
• Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

  2008cited by this paper
• Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

  2008cited by this paper
• HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

  2008cited by this paper
• Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).

  2008cited by this paper
• FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.

  2007cited by this paper
• An acetylation site in the middle domain of Hsp90 regulates chaperone function.

  2007cited by this paper
• Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors

  2005cited by this paper
• Sur la formation de la thyroxine et de ses précurseurs dans les iodoprotéines et les iodopeptones. II

  1949cited by this paper

• HDAC6 regulates the protein stability and tumor suppressor function of HIPK2 independently of its deacetylase activity.

  2026cites this paper
• Differential transcriptomic modulation by histone deacetylase inhibitor SAHA in LUAD and LUSC

  2026cites this paper
• Structure-Based Discovery of Hsp90/HDAC6 Dual Inhibitors Targeting Aggressive Prostate Cancer

  2025cites this paper
• Histone deacetylase 6: a potential therapeutic target for drug development.

  2025cites this paper
• Selective HDAC6 Inhibition by Mesinostat Impairs Tumor Growth and Stemness in Triple-Negative Breast Cancer.

  2025cites this paper
• Pharmacologically induced proteolysis of histone deacetylase-6 attenuates influenza virus replication despite limited anti-tumor effects.

  2025cites this paper
• Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications

  2025cites this paper
• Genetic deletion of histone deacetylase 6 prevents peritoneal fibrosis via suppression of heat shock protein 90 deacetylation

  2025cites this paper
• Design, synthesis and antitumor activity study of tubulin/HDAC6 dual targeting inhibitor

  2025cites this paper
• PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond

  2024cites this paper
• Acetylation of the yeast Hsp40 chaperone protein Ydj1 fine-tunes proteostasis and translational fidelity

  2024cites this paper
• Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease.

  2024cites this paper
• Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

  2024cites this paper
• Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity.

  2024cites this paper
• Searching for Novel HDAC6/Hsp90 Dual Inhibitors with Anti-Prostate Cancer Activity: In Silico Screening and In Vitro Evaluation

  2024cites this paper
• Biological and structural investigation of tetrahydro-β-carboline-based selective HDAC6 inhibitors with improved stability.

  2024cites this paper
• Acetylation of the yeast Hsp40 chaperone protein Ydj1 fine-tunes proteostasis and translational fidelity

  2024cites this paper
• Targeting apoptosis in clear cell renal cell carcinoma.

  2024cites this paper
• Investigating the role of HSP90 in cancer cell phenotypic plasticity

  2024cites this paper
• Colony Formation Assay to Test the Impact of HDACi on Leukemic Cells.

  2023cites this paper
• Advances in the Mechanistic Study of the Control of Oxidative Stress Injury by Modulating HDAC6 Activity

  2023influential citation
• Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Studies

  2023cites this paper
• Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53.

  2023cites this paper
• Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors

  2022cites this paper
• Functional stratification of cancer drugs through integrated network similarity

  2022cites this paper
• Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

  2022cites this paper
• Targeting the lncMST-EPRS/HSP90AB1 complex as novel therapeutic strategy for T-2 toxin-induced growth retardation.

  2022cites this paper
• High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma

  2022cites this paper
• AR12 increases BAG3 expression via ER stress signaling which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy

  2022cites this paper
• AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy

  2022cites this paper
• HDAC6: A unique HDAC family member as a cancer target

  2022cites this paper
• The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention

  2022cites this paper
• HDAC6 is a prognostic biomarker that mediates IL-13 expression to regulate macrophage polarization through AP-1 in oral squamous cell carcinoma

  2022cites this paper
• Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases

  2022cites this paper
• Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.

  2022cites this paper
• MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses

  2022cites this paper
• Functional Strati�cation of Cancer Drugs through Integrated Network Similarity

  2022cites this paper
• Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis

  2022cites this paper
• Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.

  2021cites this paper
• Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3

  2021cites this paper
• DNA-PKcs inhibition impairs HDAC6-mediated HSP90 chaperone function on Aurora A and enhances HDACs inhibitor-induced cell killing by increasing mitotic aberrant spindle assembly

  2021cites this paper
• Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90

  2021cites this paper
• How Influenza Virus Uses Host Cell Pathways during Uncoating

  2021cites this paper
• HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity

  2021cites this paper
• MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis

  2021cites this paper
• Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

  2021cites this paper
• Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.

  2021cites this paper
• Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

  2021cites this paper
• Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.

  2021cites this paper
• TYK2 Activating Alterations in Acute Lymphoblastic Leukemia: Novel Driver Oncogenes with Potential Avenues for Precision Medicine?

  2021cites this paper
• Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.

  2021cites this paper
• Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors

  2021cites this paper
• Dual inhibitors of Histone Deacetylases and Other Cancer-Related Targets: A Pharmacological Perspective.

  2020cites this paper
• Recent advances in small molecular modulators targeting histone deacetylase 6

  2020cites this paper
• 17-AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA-MB-231 breast cancer cells

  2020influential citation
• HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

  2020cites this paper
• Hsp90 regulates the HDAC3-dependent gene transcription while HDAC3 regulates the functions of Hsp90.

  2020cites this paper
• The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV‐infected patients on suppressive antiretroviral therapy

  2020cites this paper
• HDAC6 as privileged target in drug discovery: A perspective.

  2020cites this paper
• HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model

  2020cites this paper
• Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.

  2019cites this paper
• Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.

  2019cites this paper
• PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ

  2019cites this paper
• Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70

  2019cites this paper
• Therapeutic Implications of Heat Shock Proteins in Cancer

  2019cites this paper
• Targeting hsp90 family members: A strategy to improve cancer cell death.

  2019cites this paper
• Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression

  2019cites this paper
• G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel

  2019cites this paper
• Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.

  2019cites this paper
• Heat-Shock Protein 90 Controls the Expression of Cell-Cycle Genes by Stabilizing Metazoan-Specific Host-Cell Factor HCFC1.

  2019cites this paper
• HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms.

  2019cites this paper
• Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer

  2019cites this paper
• Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies

  2019influential citation
• HDAC6 as a potential therapeutic target for peripheral nerve disorders

  2018cites this paper
• 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.

  2018cites this paper
• HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation

  2018cites this paper
• The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines

  2018cites this paper
• Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.

  2018cites this paper
• SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules

  2018cites this paper
• Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90

  2018cites this paper
• Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics.

  2018cites this paper
• Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.

  2018cites this paper
• HDAC6 interacts with PTPN1 to enhance melanoma cells progression.

  2018cites this paper
• The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells

  2018cites this paper
• Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.

  2018cites this paper
• Neomorphic mutations create therapeutic challenges in cancer

  2017cites this paper
• Role of histone deacetylases 6 (HDAC6) in cancers.

  2017cites this paper
• New Mechanism Based Approaches For Treating Prostate Cancer

  2017cites this paper
• Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors

  2017cites this paper
• Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.

  2017cites this paper
• Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications

  2017cites this paper
• Cellular defence or viral assist: the dilemma of HDAC6.

  2017cites this paper
• The interplay between histone deacetylases and rho kinases is important for cancer and neurodegeneration.

  2017influential citation
• Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.

  2017cites this paper
• ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.

  2017cites this paper
• Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway

  2017cites this paper
• HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

  2017cites this paper
• How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.

  2017cites this paper
• Generation and Assessment of Fusions Between HDACi and TKi.

  2017cites this paper
• Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.

  2017cites this paper